Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
1.540
-0.030 (-1.91%)
At close: Oct 14, 2025, 4:00 PM EDT
1.550
+0.010 (0.65%)
After-hours: Oct 14, 2025, 7:34 PM EDT
Mainz Biomed Revenue
Mainz Biomed had revenue of $286.72K in the half year ending June 30, 2025, a decrease of -42.55%. This brings the company's revenue in the last twelve months to $659.94K, down -28.05% year-over-year. In the year 2024, Mainz Biomed had annual revenue of $893.99K, down -0.17%.
Revenue (ttm)
$659.94K
Revenue Growth
-28.05%
P/S Ratio
5.38
Revenue / Employee
$25,382
Employees
26
Market Cap
6.30M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 893.99K | -1.49K | -0.17% |
Dec 31, 2023 | 895.48K | 365.60K | 69.00% |
Dec 31, 2022 | 529.88K | -47.47K | -8.22% |
Dec 31, 2021 | 577.35K | 83.78K | 16.98% |
Dec 31, 2020 | 493.57K | 212.17K | 75.40% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MYNZ News
- 6 days ago - Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - GlobeNewsWire
- 6 weeks ago - Mainz Biomed Announces Registration of ColoAlert in the United Kingdom - GlobeNewsWire
- 2 months ago - Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert® - GlobeNewsWire
- 2 months ago - Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewsWire
- 2 months ago - Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies - GlobeNewsWire
- 3 months ago - Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition - GlobeNewsWire
- 3 months ago - Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test - GlobeNewsWire
- 4 months ago - Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - GlobeNewsWire